Lumen Bioscience awarded $16.2 million to advance C. difficile treatment
Lumen Bioscience has been granted $16.2 million by the U.S. Department of Defense to advance its C. difficile infection (CDI) treatment.
Archives for October 17, 2023
SpliceBio partners with Spark Therapeutics to develop gene targeting retinal disease
SpliceBio, a genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has partnered with Spark Therapeutics to develop a gene therapy for an inherited retinal disease.
Antiverse and GlobalBio extend collaboration to advance antibody cancer therapeutics
Antiverse, a biotech company developing a computational antibody drug discovery platform, is extending its collaboration with GlobalBio, an antibody engineering company, to advance immune checkpoint inhibitors in cancer therapy.
Bolt Biotherapeutics to present cancer immunotherapy data at ESMO 2023
Bolt Biotherapeutics, a San Francisco based company developing a platform for cancer immunotherapy, will present its phase 1/2 dose escalation study of BDC-1001 at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, being held in...